I’ve spent 11 years in pharma commercial operations and managed markets. I’ve sat through thousands of slides, attended enough advisory boards to lose my sense of taste, and spent way too long staring at spreadsheets of "who actually showed up" versus "who we invited."
One recurring failure keeps me up at night: the persistent, stubborn belief that coverage vs. adoption are the same thing. They aren't. Treating them as the same is why your launch failed, why your HEOR data is sitting on a shelf, and why your field teams are frustrated.
The Payer Permission Slip (Coverage)
Payer coverage is the permission slip. That is it. When you are presenting at an AMCP congress, you are playing the game of risk mitigation and budget impact. You are explaining why a payer shouldn't reject the drug. It is a technical, mathematical exercise centered on HTA (Health Technology Assessment) pressure, rebates, and medical necessity.
Coverage is binary. You are either on the formulary or you aren't. You are either covered with a Prior Authorization (PA) or you are restricted to step-therapy. This is the realm of the national account manager and the director of managed care. It is dry, it is transactional, and it is entirely necessary—but it doesn't move a single prescription.
The System Execution (Adoption)
If coverage is the permission, adoption is the behavior change. You can have a Tier 2 status on every major formulary in the country and still fail if the health system doesn't buy in. This is where The Health Management Academy (THMA) and the Association of Cancer Care Centers (ACCC) enter the picture.
Health systems—specifically the oncology networks and IDNs I track—don't care about your national contract. They care about their internal clinical pathways, their electronic health record (EHR) integration, and their staffing burden. Health system access execution is not about convincing a formulary committee; it’s about convincing the pharmacy director and the chief medical officer that your drug won't break their oncology care model.
The Real World Differences
To keep things straight, I maintain a running spreadsheet of these differences. It helps me stop teams from wasting time on the wrong stakeholders. Here is how they break down:
Feature Payer Coverage Health System Adoption Primary Goal Mitigate formulary exclusion Embed into clinical pathways Key Audience Payer Medical Directors, Pharmacy Benefits Managers CMOs, Dept. Heads, Nursing staff, Billing managers Success Metric Formulary placement status Actual dispense volume within the system Primary Constraint Budget impact, HTA pressure Operational burden, EHR integrationThe Digital Friction Problem
We love talking about digital tools in evidence generation and reimbursement. But let’s be honest: most of what we build is digital noise. We provide portals that are as frustrating as those persistent Cookie Law Info plugin UI elements you see on every website scrape—endless consent banners and pop-ups that nobody reads before clicking "Accept" just to get to the content.
When your commercial team market access materials are buried behind a clunky portal, you aren't helping. You’re adding friction. If a doctor or a pharmacist has to navigate a labyrinth of digital terms and conditions just to find a simple dosage guide, they will just move to a competitor’s product. Stop building "portals." Start building tools that actually provide value at the point of care.
Pricing, Affordability, and HTA Pressure
The conversation around pricing has shifted. Payers are no longer just looking at the WAC (Wholesale https://pharmashots.com/33979/pharma-market-access-conferences-2026/ Acquisition Cost). They are looking at the total cost of care. If you have a high-priced therapy, you better have a story about how it saves the health system money on downstream events.
At ACCC-style roundtables, the conversation is rarely about the list price. It is about the "cost to manage." If your drug requires three staff members to coordinate the PA process, the health system will adopt a cheaper, less effective alternative that is easier to manage. Your pricing strategy must account for the operational burden it places on the provider. If it takes a department two weeks to clear the paperwork, your drug isn't adopted. It’s a liability.
The Monday Morning Reality Check
Every time I attend a major conference—whether it’s AMCP or a specialized health system forum—I ask myself the same question: "What would I do differently on Monday?"
Most people leave a conference with a notebook full of "synergy" and "streamline" buzzwords. That’s useless. If you want to actually improve your market access execution, do these three things when you get back to the office:
Audit your HCP-facing materials: If your field reps are showing a slide deck designed for a Payer Director to a busy Oncologist, fire the marketing team. They are speaking two different languages. Check your "Real" Data: Stop looking at national claims data for a second. Look at your dispense data within a specific health system. Why is one IDN adopting your drug and the one 50 miles away isn't? The answer is almost always operational, not clinical. Pressure Test your PA Process: Spend an hour trying to get your own drug approved through an average health system's workflow. If you can’t do it in under 15 minutes, your drug isn't "accessible." It’s a chore.Conclusion
Stop overpromising ROI based on national coverage lists. Coverage is just the gatekeeper's blessing. Adoption is the work of winning over the people who actually prescribe and dispense the product. It’s hard, messy, and requires you to actually understand the daily grind of a health system administrator.
Next time you are planning your strategy, forget the fluff. Focus on the workflow. Who is actually typing the order? What screen are they looking at? What happens if the system denies the request? If you don't know the answer to those three questions, your "market access" plan is just a theory.